|
🐜
|
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
42 auth.
D. Owen,
C. Allerton,
A. Anderson,
L. Aschenbrenner,
M. Avery,
S. Berritt,
B. Boras,
R. Cardin,
A. Carlo,
K. Coffman,
A. Dantonio,
L. Di,
H. Eng,
R. Ferre,
K. Gajiwala,
...
S. Gibson,
S. Greasley,
B. Hurst,
E. Kadar,
A. Kalgutkar,
J. C. Lee,
J. Lee,
W. Liu,
S. Mason,
J. Novak,
R. Obach,
K. Ogilvie,
N. Patel,
M. Pettersson,
D. Rai,
M. Reese,
M. Sammons,
J. Sathish,
R. Singh,
C. Steppan,
A. Stewart,
J. Tuttle,
L. Updyke,
P. Verhoest,
L. Wei,
Q. Yang,
Y. Zhu
|
10 |
2021 |
10
🐜
|
|
🐜
|
Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
7 auth.
A. Stepan,
Daniel P. Walker,
J. Bauman,
David A. Price,
T. Baillie,
A. Kalgutkar,
...
M. Aleo
|
9 |
2011 |
9
🐜
|
|
🦁
|
A comprehensive listing of bioactivation pathways of organic functional groups.
13 auth.
A. Kalgutkar,
I. Gardner,
R. Obach,
C. L. Shaffer,
Ernesto Callegari,
K. Henne,
A. Mutlib,
D. Dalvie,
J. S. Lee,
Y. Nakai,
...
J. O'Donnell,
J. Boer,
S. Harriman
|
9 |
2005 |
9
🦁
|
|
🐬
|
Arachidonic Acid Oxygenation by COX-1 and COX-2
L. Marnett,
S. Rowlinson,
D. Goodwin,
A. Kalgutkar,
C. Lanzo
|
9 |
1999 |
9
🐬
|
|
🐬
|
Biotransformation reactions of five-membered aromatic heterocyclic rings.
D. Dalvie,
A. Kalgutkar,
S. Khojasteh-Bakht,
R. Obach,
J. O'Donnell
|
8 |
2002 |
8
🐬
|
|
🦁
|
Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors.
A. Kalgutkar,
Alan B. Marnett,
B. Crews,
R. Remmel,
L. Marnett
|
8 |
2000 |
8
🦁
|
|
🐜
|
A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385*
9 auth.
S. Rowlinson,
J. Kiefer,
J. Prusakiewicz,
J. Pawlitz,
K. Kozak,
A. Kalgutkar,
...
W. Stallings,
R. Kurumbail,
L. Marnett
|
8 |
2003 |
8
🐜
|
|
🐜
|
On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds
17 auth.
T. R. White,
Chad M. Renzelman,
Arthur C. Rand,
Taha Rezai,
Cayla M. McEwen,
V. Gelev,
Rushia A. Turner,
Roger G. Linington,
S. Leung,
A. Kalgutkar,
...
J. Bauman,
Yizhong Zhang,
S. Liras,
David A. Price,
A. Mathiowetz,
M. Jacobson,
R. Lokey
|
8 |
2011 |
8
🐜
|
|
🦁
|
Aspirin-like molecules that covalently inactivate cyclooxygenase-2.
A. Kalgutkar,
B. Crews,
S. Rowlinson,
Carlos Garner,
Karen Seibert,
L. Marnett
|
8 |
1998 |
8
🦁
|
|
🦁
|
Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors.
7 auth.
A. Kalgutkar,
B. Crews,
S. Rowlinson,
Alan B. Marnett,
K. Kozak,
R. Remmel,
...
L. Marnett
|
7 |
2000 |
7
🦁
|
|
🦁
|
Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
A. Kalgutkar,
R. Obach,
T. Maurer
|
7 |
2007 |
7
🦁
|
|
🐜
|
Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice.
30 auth.
E. Cokorinos,
Jake E. Delmore,
A. Reyes,
Bina Albuquerque,
R. Kjøbsted,
Nicolas O. Jørgensen,
Jean-Luc Tran,
Aditi Jatkar,
Katherine Cialdea,
Ryan M. Esquejo,
John K. Meissen,
M. Calabrese,
Jason S. Cordes,
R. Moccia,
D. Tess,
...
Christopher T. Salatto,
Timothy M. Coskran,
A. Opsahl,
Declan Flynn,
M. Blatnik,
Wenlin Li,
E. Kindt,
M. Foretz,
B. Viollet,
J. Ward,
R. Kurumbail,
A. Kalgutkar,
J. Wojtaszewski,
K. O. Cameron,
Russell A. Miller
|
7 |
2017 |
7
🐜
|
